NEXTBIOMEDICAL Co., Ltd. Logo

NEXTBIOMEDICAL Co., Ltd.

Develops medical devices using a proprietary biodegradable polymer technology platform.

389650 | KO

Overview

Corporate Details

ISIN(s):
KR7389650003
LEI:
Country:
South Korea
Address:
인천광역시 연수구 벤처로100번길 6, 인천광역시

Description

NEXTBIOMEDICAL Co., Ltd. is a company specializing in the development and commercialization of innovative therapeutic solutions, with a focus on drug-device combination products. The company's core competency is its proprietary polymer technology platform, which includes biodegradable adhesive polymers and resorbable microspheres. These technologies are applied to create first-in-class medical devices that address unmet clinical needs. Key product applications include advanced hemostatic agents for endoscopic procedures and embolic materials for interventional pain management and vascular therapies, such as genicular artery embolization for osteoarthritis pain.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2024-12-04 00:00
주식등의대량보유상황보고서(약식)
Korean 81.1 KB
2024-11-28 00:00
기타경영사항(자율공시) (미국 식품 의약국 (FDA) 의료기기 (2등급) 품목허가 취득)
Korean 5.3 KB
2024-11-15 00:00
주식등의대량보유상황보고서(약식)
Korean 67.8 KB
2024-11-14 00:00
분기보고서 (2024.09)
Korean 806.5 KB
2024-10-07 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.7 KB
2024-10-07 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.8 KB
2024-10-07 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.8 KB
2024-08-28 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.0 KB
2024-08-28 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.0 KB
2024-08-27 00:00
주식등의대량보유상황보고서(약식)
Korean 61.7 KB
2024-08-27 00:00
주식등의대량보유상황보고서(일반)
Korean 88.2 KB
2024-08-27 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.0 KB
2024-08-27 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.0 KB
2024-08-27 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.0 KB

Automate Your Workflow. Get a real-time feed of all NEXTBIOMEDICAL Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NEXTBIOMEDICAL Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NEXTBIOMEDICAL Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.